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ABSTRACT  
Stress ulcer prophylaxis (SUP) is an important part of management of critically ill 
patients in Intensive Care Unit (ICU). However inappropriate use of these drugs has 
important clinical implications such as ventilator-associated pneumonia (VAP) and 
gastrointestinal tract (GIT) infections to name a few. Strict adherence to guidelines is 
the corner stone to gaining maximal desired clinical effect with minimal adverse events. 
The overuse of proton pump inhibitors (PPIs) as SUP is a rapidly growing problem 
internationally. In Chris Hani Baragwanath Academic Hospital (CHBAH), Charlotte 
Maxeke Johannesburg Academic Hospital (CMJAH) and Helen Joseph Hospital (HJH) 
there are no studies that have been conducted to investigate this. 
 
The aim of this study was to describe the use of PPIs in ICU patients at CHBAH, 
CMJAH and HJH over a three-month period. 
 
A retrospective, descriptive, contextual study design was used. Data were collected 
from ICU charts of adult patients admitted to CHBAH, CMJAH and HJH ICUs that 
fulfilled the inclusion criteria. Data were collected over a three-month period. 
  
A total of 174 patients were included in the study. Of these patients 156 were on SUP, 
95 (60.9%) were appropriately started on SUP and 61 (39.1%) were inappropriately on 
SUP. This shows overuse of SUP. The number of patients that actually qualified for 
SUP according to the ASHP guidelines was 113. In that group of patients only 32 
(28.3%) were on PPIs and the remainder of the patients 81 (71.7%) were either on 
other agents or were not on any SUP, reflecting an underuse of PPIs. 
 
Our study found inappropriate overuse of SUP according to the ASHP guidelines, 
however there were patients who qualified for SUP but were not on SUP. In the group 
of patients that were appropriately on SUP, a large number of them were on other 
agents and not PPIs even though it is the drug of choice.   
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CHAPTER ONE  
OVERVIEW OF THE STUDY 
 
1.1 Introduction 
In this chapter the background, problem statement, aim and objectives, research 
assumptions and definitions, ethical considerations, demarcation of study field, research 
methodology, significance of the study as well as validity and reliability are discussed.  
 
1.2 Background 
 Since the 1800s, ICU patients have been shown to develop gastric ulceration secondary 
to physiological stress. The aetiology of stress ulcer is multifactorial. A prominent factor in 
the development of stress ulcers is the development of splanchnic hypoperfusion. This 
occurs as a result of the body’s stress response to critical illness. The stress response 
involves the activation of the sympathetic nervous system, an increase in circulating 
catecholamines, vasoconstriction, hypovolaemia, a decrease in cardiac output and an 
increase in pro-inflammatory cytokines (1) are some of the factors that contribute to the 
development of stress ulcers in critically ill patients (2). The overall effect of these 
substances is a decrease in the blood flow to the gastrointestinal system, which results in 
a decrease in oxygen and bicarbonate delivery, which promotes damage to gastric 
mucosa (1). Gastrointestinal hypoperfusion leads to a decrease in peristalsis which delays 
removal of acid, increasing exposure of the damaged mucosa to acid and amplifying the 
risk of developing stress ulcers (3-5). Bleeding from stress ulcers increases morbidity thus 
prolonging ICU stay of patients by four to eight days. It also has an impact on mortality 
rate with a relative risk of 1-4 (6). Each episode of CSB results in additional 
haematological tests and a mean of eleven blood products transfusion leading to 
increased medical cost overall (6, 7). 
                    
There are certain factors that put the critically ill patients in ICU at increased risk for 
developing a stress ulcer. Major factors independently predispose patients to stress ulcers 
such as mechanical ventilation for more than 48 hours and coagulopathy (4, 8, 9). 
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Minor risk factors have an additive effect of increasing the risk of developing stress ulcers 
and they are: sepsis, burns, renal failure, hepatic failure, the use of high dose 
glucocorticoids, heparin or warfarin and spinal cord injury (1, 8). According to the 
guidelines prophylaxis is indicated in ICU patients with the following: mechanical 
ventilation for more than 48 hours, coagulopathy and patients with more than one minor 
risk factors (2, 8). 
 
Proton pump inhibitors (PPIs) have proved to be the most superior in efficacy for stress 
ulcer prophylaxis (SUP) and have gained widespread use (10). The low intra gastric pH 
plays a pivotal role in the pathophysiology of stress ulcers (3). PPIs can produce 
sustained suppression of acid secretion that is dose dependent and their efficacy grows 
exponentially with continuous use without tachyphylaxis (11). The other agents used as 
SUP do not produce these results (12).  
 
International literature shows that there is a tendency to overuse PPIs in ICU (13-15). In a 
retrospective study by Farrel et al (4) 68% of patients without any risk factors were placed 
on prophylaxis on ICU admission, This raises concerns of drug-drug interactions, adverse 
effects such as hospital acquired pneumonia (16) and costs (17). No literature detailing 
the extent of the use of PPIs in South African ICUs could be identified. 
 
1.3 Problem statement 
It is well documented that patients in ICU are at an increased risk of developing stress 
ulcers (4).  PPIs are regarded as the drug of choice for prophylaxis (10), and overuse of 
these drugs has serious medical implications as mentioned in the introduction. 
 
There are guidelines in terms of risk stratification as to which patient should be put on 
prophylaxis for stress ulcers (8). Despite good intentions, there is often a gap between 
evidenced based guidelines and actual clinical practice (18) . The use of PPIs is one area 
where such a gap exists. It has been shown internationally that prophylaxis for stress 
ulcers is still overused in ICU (4). Nardino et al (14) showed that up to 65% of patients 
receive stress ulcer prophylaxis without any risk factors in the general medical unit. It is 
not known whether PPIs are overused in the ICUs of South African hospitals, specifically 
Chris Hani Baragwanath Academic Hospital (CHBAH), Charlotte Maxeke Johannesburg 
Academic Hospital (CMJAH) and Helen Joseph Hospital (HJH). 
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1.4 Aim and objectives of the study 
1.4.1 Aim 
The aim of this study was to describe the use of PPIs in ICU patients at CHBAH, CMJAH 
and HJH over a three-month period. 
 
1.4.2 Objectives 
The objectives of this study were to: 
• describe the use of SUP in these ICUs 
• describe the risk factors that necessitate the initiation of SUP 
• describe the SUP received by patients with no risk factors 
• describe the risk factors in those patients inappropriately not on SUP 
• describe the appropriate use of PPIs in ICU versus the inappropriate use according to 
the risk factors of the patient as per ASHP guidelines. 
 
1.5 Research assumptions and definitions 
The following definitions will be used in this study. 
 
Stress ulcer: damage to the gastric mucosa caused by physiological stress (8). 
 
Risk factors associated with stress ulcer development:  ASHP Therapeutic Guidelines 
on Stress Ulcer Prophylaxis (8) categorise the risk factors into major  and minor risk 
factors. 
 
Major risk factors are: mechanical ventilation for more than 48 hours and coagulopathy. 
 
Minor risk factors are: sepsis, burns, renal failure, hepatic failure, use of high dose  
glucocorticoids, heparin, warfarin, major surgery and spinal cord injury. 
 
Stress ulcer prophylaxis: administration of two or more doses of H2RA, antacids, 
sucralfate, prostaglandin analogues or PPIs (9). 
 
Appropriate use of PPIs: the presence of one or more major risk factor or the presence 
of more than one minor risk factor or presence of both major and minor risk factors.  
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Inappropriate use of PPIs: presence of only one minor risk factor or the absence of risk 
factors. For the purpose of this study omission of treatment in patients who qualified for 
SUP was classified as inappropriate. 
 
Mechanical ventilation: use of ventilator or respirator to improve the exchange of air 
between the lungs and the atmosphere. 
 
Coagulopathy:  platelet count of less than 50,000 mm3, an International Normalised 
Ratio of more than1.5, or a partial thromboplastin time of more than 2 times the control 
value control (8). 
 
SIRS: two or more of the following, temperature of more 38°C or less than 36°C, heart 
rate of more 90 beat per minute, respiratory rate of more than 20 breaths per minute, 
white cell count of more than12 000 mm -3 or less than 4000 mm -3 (19). 
 
Sepsis: SIRS plus source of infection (19). 
 
Burns: injury involving more than 35% of body surface area (8). 
 
Renal failure: a creatinine clearance less than 40 ml/min or serum creatinine more than 
2.8 mg/dl (141,1 mmol/l) (4).  
 
Hepatic failure: aspartate aminotransferase of more than 500 U/L or total bilirubin of 
more than 8.8 mg/dl (150.5 umol/l) (4). 
 
Major surgery: surgery lasting more than 4 hours (4). 
 
High dose corticosteroids: an equivalent of more than 250 mg of hydrocortisone per 
day (8). 
 
Spinal cord injury: trauma or disease that affects the conduction of sensory and motor 
signal across the site(s) of lesion(s) (20). 
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Adult patients: participants who are 18 years and older. 
 
1.6 Ethical considerations 
Ethical approval to conduct this study was obtained from the relevant authorities 
(appendix 1). Consent to perform the study was obtained from the relevant authorities 
(Appendix 2,3,4& 5).  
 
The researcher observed the principles of the Declaration of Helsinki (21) and the South 
African Good Clinical Practice Guidelines (22). 
 
1.7 Demarcation of the study field 
The study was conducted at CHBAH, CMJAH and HJH in Johannesburg, Gauteng. 
CHBAH and CMJAH are central hospitals and HJH a tertiary hospital. All three hospitals 
are affiliated to the University of the Witwatersrand. These are multidisciplinary ICUs in 
these hospitals. 
 
1.8 Research methodology 
1.8.1 Research design 
A retrospective, descriptive, contextual study design was used. 
 
1.8.2 Study population 
The ICU charts of adult patients admitted to CHBAH, CMJAH and HJH ICUs that fulfilled 
the inclusion criteria formed the population group studied, data was collected over a three-
month period. 
 
1.8.3 Study sample 
Sample size 
The number of patients admitted into the ICUs over a three-month period will determine 
sample size. 
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 Sampling method 
Convenience, consecutive sampling of ICU charts was used.  
 
1.8.4 Inclusion and exclusion criteria  
 Inclusion criteria 
All complete and legible ICU charts of adult patients admitted to these selected ICU’s 
during the study period. 
 
 Exclusion criteria 
The ICU charts of patients with the following will be excluded: 
• existing upper gastrointestinal bleeding 
• previous total gastrectomy 
• died or discharged within 24 hours of admission 
• on PPIs prior to admission. 
 
1.8.5 Data collection 
A data collection sheet (Appendix 8) was used to collect data from ICU charts of patients 
admitted into ICU during the study period. 
 
The researcher collected the data personally and the data were entered into a Microsoft 
Excel® spreadsheet. Data were collected from ICU charts dated from 1st August up to and 
including 31st October 2013. However since this was a retrospective study the actual 
physical collection of data were from November 2013.   
 
1.8.6 Data analysis 
 Data were analysed in consultation with a biostatistician using STATA 12.5.  
   
1.9 Significance of the study 
SUP in patients at high risk for developing stress ulcer not only improves morbidity and 
mortality (9) but it is also cost effective in that it reduces financial burden to health (23). 
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However the drugs used for SUP have side effects with significant consequences 
therefore it is imperative that guidelines for SUP are adhered to and the risk: benefit ratio 
for each patient is assessed (24). 
 
This study may give insight into the PPI prescribing practices. If they are inappropriately 
prescribed according to the guidelines, feedback measures such as educational strategies 
and awareness can be put in place. 
 
1.10 Validity and reliability 
Measures were taken to ensure the validity and reliability of this study. 
 
1.11 Study outline 
The outline of this study is as follows: 
• Chapter 1: Overview of the study 
• Chapter 2: Literature review 
• Chapter 3: Research methodology 
• Chapter 4: Results and discussion 
• Chapter 5: Summary, limitations, recommendations and conclusion. 
 
1.12 Summary 
In this chapter an overview of the background, problem statement, aim and objectives, 
research assumptions, demarcation of study field, ethical considerations, research 
methodology, significance, validity and reliability, and study outline was presented. The 
following chapter will discuss literature review of this study.
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CHAPTER TWO  
LITERATURE REVIEW 
2.1 Introduction 
In this chapter the literature on stress ulcer prophylaxis is reviewed. This includes the 
physiology of gastric acid secretion, pathophysiology, risk factors, and stress ulcer 
prophylaxis. Pharmacology of PPIs as well as the use, benefits, adverse effects and 
overuse of PPIs and the ASHP guidelines are also discussed.  
 
2.2 Physiology of gastric acid secretion 
Stomach acid is secreted by parietal cells. The parietal cells are enriched with 
mitochondria, which are essential for generation of energy required for hydrogen ion 
secretion by tubulovesicular and canaliculi structures. These structures contain hydrogen 
ion pumps, which are H/K ATPase pumps that exchange hydrogen ions for potassium 
ions across the apical membrane. At rest the parietal cell cytoplasm is filled with 
tubulovesicular structures. When stimulated the tubulovesicles coalesce into canaliculi 
and become filled with microvilli. This results in the membrane area of the canaliculi 
draining to the apical surface of the parietal cells in preparation for high rates of acid 
secretion. Upon withdrawal of stimulation the canaliculi collapse and microvilli recede (25, 
26). Figure 2.1 illustrates the different phases of a parietal cell. 
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Figure 2.1 Parietal cells in the various phases (27) 
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The different pathways that are involved in acid secretion are as follows:  	  
• Parasympathetic nervous system via the vagus nerve: stimulation of the cholinergic 
activity promotes the stimulatory mechanisms that lead to the activation of parietal 
cells and gastrin release from G-cells     
• Paracrine pathway: the enterochromaffin-like cells (ECL) secrete histamine that 
activates H2 receptors.  
• Endocrine pathway: gastrin that is produced by G-cells around the antrum stimulates 
parietal cells in the antral mucosa through histamine release and also has tropic 
activity towards ECL that increases the release of stored histamine.  
• Somatostatin: inhibit histamine release and gastrin release from ECL and G cells (28). 
 
Binding of histamine to H2 receptors of the parietal cells stimulates cell function by 
increasing cyclic AMP-dependent protein kinases. Acetylcholine and gastrin appear to 
stimulate the parietal cells by stimulating the release of additional cytosolic calcium in the 
parietal cells (26, 29). 
 
The sight, smell and/or taste of food results in an increase in vagal efferent activity and 
the release of acetylcholine. Acetylcholine directly increases acid production by 
stimulating the parietal cells. The presence of food in the stomach increases acid 
production in various ways. Food stimulates the G cells to secrete gastrin. Gastrin has a 
tropic action on the parietal cells causing them to enlarge, it also stimulates the ECL cells 
to produce histamine that increases acid production from the parietal cells. Secondly 
gastric distension caused by food excites a long vagal reflex to release more acetylcholine 
(25). 
 
A pH below 2,5 in the antrum inhibits the release of gastrin and once the pH is below 1,2 
gastrin secretion is completely blocked. This is a negative feedback pathway (14). Figure 
2.2 demonstrates the various pathways involved in gastric acid secretion. 
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Figure 2.2 Pathways involved in gastric acid secretion 
Adapted from BMJ Publishing Group Ltd 
 
 
2.3 Pathophysiology of stress related mucosal disease 
The pathophysiology of stress related mucosal disease (SRMD) is multifactorial. The 
interaction of these multiple factors causes a breakdown of mucosal defenses leading to 
damage of the mucosa by the aggressive physiological factors (1). 
 
A prominent factor in the development of stress ulcer is the development of splanchnic 
hypoperfusion. This occurs as a result of the body’s stress response to critical illness. The 
stress responses include activation of the sympathetic nervous system, increase in 
circulating catecholamine, vasoconstriction, hypovolaemia, decrease in cardiac output and 
increase in proinflammatory cytokines (1).  
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The overall effect of these substances is to redistribute blood flow from the gastrointestinal 
system and skin to more essential organs such as the brain, heart and kidneys. This 
response is beneficial initially, but as the response continues, the decrease in splanchnic 
blood flow results in a decrease in oxygen delivery and bicarbonate, which promote 
damage to gastric mucosa. The permeability of the mucosa is compromised and the 
backflow of hydrogen ions and pepsin further damages the mucosa. Gastrointestinal 
hypoperfusion leads to a decrease in peristalsis which delays removal of acid, increasing 
exposure of the damaged mucosa to acid and amplifying the risk of developing stress 
ulcer (1-3, 30).  
 
A further contributing factor is reperfusion injury. After a prolonged period of 
hypoperfusion, when blood flow is restored, the increase in nitric oxide synthetase leads 
to hyperaemia, cell death and an increased inflammatory response, which leads to further 
mucosal damage (2, 3). 
 
Mechanical ventilation has adverse effects on splanchnic haemodynamics, when PEEP is 
used. PEEP decreases mesenteric blood flow by decreasing cardiac output (2, 3, 5).  
 
2.4 Risk factors for developing a stress ulcer 
The University of Arizona under contract of ASHP prepared the ASHP Therapeutic 
Guidelines on Stress Ulcer Prophylaxis in November 1998. A literature search on Medline 
from the period 1966 -1997 was done and International Pharmaceutical Abstracts (IPA) 
from 1970-1997 were used. The authors then compiled risk factors from the data 
collected. These guidelines are the only existing guidelines for SUP since 1999. They 
have never been updated since their publication and therefore some recommendations 
are outdated. They are discussed further in section 2.7 of this document (8).  
 
The two major risk factors are those that can individually predispose patients to stress 
related mucosal disease (SRMD) such as mechanical ventilation for more than 48 hours 
and coagulopathy, defined as a platelet count of <50,000 mm3, an International 
Normalised Ratio of >1.5, or a partial thromboplastin time of >2 times the control value (1, 
8, 9). When these risk factors are present the frequency of bleeding is 3.7%, compared to 
those patients without which is 0.1% (9). 
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Minor risk factors are those that, while individually they do not increase the risk of ulcer 
formation, when added together they increase the risk of developing stress ulcers. These 
minor risk factors include sepsis, burns, renal failure, hepatic failure, the use of 
glucocorticoids (>250mg per day of hydrocortisone or the equivalent), heparin, warfarin, 
and spinal cord injury (1, 8). Patients with minor risk factors only, have an extremely low 
risk of developing clinically important bleeding 0.1-0.5% (9).  
 
2.5 Stress ulcer prophylaxis 
Prophylaxis for stress ulcer is the administration of two or more doses of H2RA, antacids, 
sucralfate, prostaglandin analogues or PPIs (9). Figure 2.3 shows the progressive drop in 
the incidence of clinically significant bleeding (CSB) secondary to SUP. The administration 
of SUP to patients with high risk reduces the relative risk of clinically significant bleeding 
by approximately 50% (9).  
 
 
 
 
CSB: clinically significant bleeding 
FDA: Food and Drug Administration  
Figure 2.3 Stress ulcer prophylaxis timeline (31)  
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The PPIs have proven to be superior in efficacy to other forms of SUP and have gained 
widespread use (10, 32). The low intra gastric pH plays a pivotal role in the 
pathophysiology of stress ulcers (3) and PPIs can produce sustained suppression of acid 
secretion that is dose dependent and their efficacy grows exponentially with continuous 
use (11). The other agents used as SUP do not produce these results. H2RA are known to 
develop tachyphylaxis within 72hours of initiation (1, 33) and do not consistently maintain 
gastric pH above 3.5 (12) which is the pH required to prevent stress ulcer related bleeding 
(8) . Another important consideration when dealing with critically ill patients is the 
pharmacokinetic/ pharmacodynamics of a drug in the face of organ dysfunction. PPIs 
have a drug within their class that does not need dose adjustment in the presence of renal 
and liver dysfunction. Both H2RA and sucralfate need dose adjustment in patients with 
renal dysfunction (12). The surviving sepsis guidelines of 2012 recommend the use of 
PPIs as the sole agent for SUP (19), unlike previous editions, which recommended the 
use of either PPIs or H2RA. This highlights the change in trend in the literature supporting 
PPIs as the drug of choice. Table 2.1 shows a summary of studies comparing the efficacy 
of PPIs versus H2RA and sucralfate. It shows a consistent trend of PPIs having a lower 
incidence of stress ulcer related CSB compared to the other agents. 
 
Table 2.1 Summary of studies looking at the efficacy of PPIs 
 
Author  
Year 
Population Intervention UGI 
Bleeding 
Powel et al. 
1993 (34) 
Post-CABG surgical ICU Omeprazole i.v. 80mg ×1,then i.v. 
40mg/day 
Omeprazole i.v. 80mg×1, then i.v. 
40mg/8h 
Ranitidine i.v. 50mg/8h 
0(0%) 
 
0(0%) 
 
0(0%) 
Levy et al.(35) 
1997 
Medical and surgical ICU Omeprazole NG 40mg/day 
ranitidine i.v. 50mgbolus,then i.v. 
50mg/day 
1(3%) 
11(35%) 
Kantorova et al 
2004 (36) 
Surgical ICU Omeprazole i.v. 40mg/day 
Famotidine i.v. 40mg/12h 
Sucralfate NG 1mg/6h 
Placebo 
1(1%) 
2(3%) 
3(4%) 
1(1%) 
Conrad et al 
2005 (37) 
General ICU Omeprazole NG 40mg×2, then NG 
40 mg/day 
Cimetidine i.v. 300mg bolus, then 
c.i.v. 1200mg/24/h 
7(4%) 
 
10(6%) 
Hata et al. 
2005 (38) 
General ICU Rabeprazole PO 10mg/day 
Ranitidine PO 300 mg/day 
Teprenone NG 150 mg/day 
0(0%) 
4(6%) 
4(6%) 
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Somberg et al 
2008 (39) 
Mixed ICU Pantoprazole i.v. 40mg/day 
Pantoprazole i.v. 40mg/12h 
Pantoprazole i.v. 80mg/day 
Pantoprazole i.v. 80mg/12h 
Pantoprazole i.v. 80mg/8h 
Cimetidine i.v. 300mg bolus, then 
c.i.v. 1200mg/12h 
0(0%) 
0(0%) 
0(0%) 
0(0%) 
0(0%) 
0(0%) 
 
Solouki and 
Kouchak 
2009 (40) 
General ICU Omeprazole NG 20mg/12h 
Ranitidine i.v. 50mg/12h 
4(7%) 
18(26%) 
Brophy et al. 
2010(41) 
ICU 
Neurosurgery 
Patients 
Lansoprazole suspension NG 
30mg/day 
Famotidine i.v. 20mg/12h 
0(0%) 
 
1(2%) 
 
 
CABG: coronary artery bypass graft; c.i.v: continuous intravenous infusion; i.v: 
intravenous; NG: nasogastric; PO: per oral; UGI: upper gastrointestinal. 
 
Alhazzani et al (7) in 2013 did a meta-analysis looking at PPIs versus H2RA for SUP in 
critically ill patients, they concluded that PPIs are more effective than H2RA in preventing 
CSB. The superiority of PPIs as stress ulcer prophylaxis is due to their more profound 
acid suppression. The pH dependent clot stabilisation prevents ulcer rebleeding (42) .  
 
2.6 Proton Pump Inhibitors 
2.6.1 Pharmacology of proton pump inhibitors 
PPIs are weak bases which selectively and irreversible inhibit the gastric H/K ATPase, the 
pKa of these drugs is between 3,8 and 4,9. This enables PPIs to accumulate selectively in 
the acidic space of the secretory canaliculi of the stimulated parietal cells, where the pH is 
about 1.0. This results in a concentration at the luminal surface of the pump that is much 
greater than blood concentration. PPIs are administered as prodrugs, which are converted 
to their active form by an acid dependent process. The active form of the drug then forms 
disulphide bonds with the H/K ATPase enzyme. It is the covalent binding with the ATPase 
that inhibits their activity (29, 42, 43). 
 
The main pharmacokinetic parameters of the commonly used PPIs are compared in the 
Table 2.2 (42). 
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Table 2.2 Pharmacokinetics of PPIs  
Parameter Omeprazol
e 
Esomeprazol
e 
Lansoprazol
e 
Pantoprazol
e 
Rabeprazol
e 
tmax (h) 1-6 1-3.5 1.2-2.1 2-4 3-5 
F (%) 25-40 
increase 
upon 
multiple 
dosing 
50 (acute 
dosing) 
70-80 
(chronic 
dosing) 
80-90 77 52 
V (l/kg) 0.13-0.35 0.22-0.26 0.4 0.15 _ 
CL (ml/min) 400-620 330 acute 
160-250 
chronic 
400-650 90-225 - 
Effect of 
age 
CL⇔ 
T1/2↑   
F↑  
CL⇔ 
T1/2 ⇔ 
CL↓ 
T1/2 ↑ 
CL⇔ 
T1/2 ⇔ 
CL↓ 
T1/2 ↑ 
Renal 
insufficienc
y 
CL⇔ 
T1/2 ⇔ 
F⇔ 
- CL⇔ 
T1/2 ↑ 
CL⇔ 
T1/2 ⇔ 
CL↑ 
T1/2 ⇔ 
Hepatic 
dysfunction 
CL↓ 
T1/2 ↑ 
F↑ 
CL↓ 
T1/2 ↑ 
CL↓ 
T1/2 ↑ 
CL↓ 
T1/2 ↑ 
F⇔ 
CL↓ 
T1/2 ↑ 
Tmax time to maximal plasma concentration, F oral bioavailability, V apparent volume of 
distribution, T1/2 elimination half-life, ↑ increase,↓ decrease ⇔ no significant change. 
 
Overall pharmacodynamics and clinical data indicated that rabeprazole could provide the 
greatest degree of acid suppression among the available PPIs. It also may provide a 
faster onset toward a maximal antisecretory effect than other drugs of this class. This can 
be of therapeutic relevance, as clinical outcome depends on extent and duration of 
secretory inhibition (42). Critically ill patients often have organ dysfunction, which impairs 
drug metabolism. They are commonly on multiple drugs, which make drug interaction an 
important consideration. Pantoprazole does not require dose adjustment in patients with 
renal failure and has low potential for drug interaction making it an ideal SUP for critically 
ill patients (12).  
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2.6.2 Uses of proton pump inhibitors 
PPIs are used to treat conditions such: 
• peptic ulcer disease  
• gastroesophageal reflux disease 
• non-steroidal anti-inflammatory drug induced gastric lesions 
• Zollinger-Ellison syndrome 
• dyspepsia.  
PPIs are also used as part of eradication therapy for Helicobacter pylori with two 
antibiotics  
Also used as first line agent for SUP (10, 42, 44). 
 
2.6.3 Administration of proton pump inhibitors 
PPIs can be administered intravenously (IV) or orally (PO). These drugs are very costly 
and there is a concern over their contribution to total health cost in ICU patients (24).        
A question has arisen of whether giving PPIs orally is inferior to intravenous 
administration, and whether this will improve health cost (45). 
 
Javid et al (46) conducted a study in the Sher-i-Kashmir Institute of Medical Science from 
May 2004-January 2007 comparing the two routes of administration, intravenous versus 
oral. The aim was to establish if one route was more efficacious than the other in 
increasing gastric pH. The authors came to the conclusion that high doses of different 
groups of PPIs given via different routes (intravenous or oral) after successful endoscopic 
therapy showed an insignificant difference among various PPIs on 72h intragastric pH, 
thus routes of administration does not influence efficacy.  
 
2.6.4 The benefits of proton pump inhibitors 
Stress ulcer related bleeding increases morbidity and mortality, and lengthen the number 
of days in ICU by four to eight days (6). Endoscopic evidence of mucosal damage is seen 
in most patients within hours of admission to the ICU.  
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The prevalence of endoscopic evident mucosal damage is 74-100%, for occult bleeding is 
15-50% and for clinically overt bleeding is 5-25% (2, 3, 9). Each episode of CSB results in 
additional haematological tests, a mean of eleven blood products transfusion resulting in 
overall increased medical cost (6). 
 
Levy et al (35) conducted a landmark study comparing omeprazole with ranitidine in 
patients with risk factors for stress ulcer related bleeding. They found significantly more 
clinically important bleeding in the ranitidine group than in the omeprazole group (31% 
versus 6%, p< 0.05) and concluded that a single oral daily dose of omeprazole was 
superior in efficacy and safety compared to continuous intravenous infusion of ranitidine. 
 
Acid suppressive therapy prevents rebleeding from stress ulcers by increasing gastric pH 
and preventing clot instability caused by gastric acid. Over the last two decades the 
incidence of stress related mucosal bleeding has decreased dramatically, however SUP 
still remains as one of the corner stones to improving clinical outcome of critically ill 
patients (1). 
  
 
2.6.5 Adverse effects of proton pump inhibitors 
One of the prominent adverse effects in patients in ICU receiving PPIs is hospital-acquired 
pneumonia. PPIs reduce gastric acidity, leading to colonisation of the upper 
gastrointestinal tract. Retrograde contamination and micro aspiration to the lower airways 
lead to infection of the lungs (47, 48).  
 
In a study by Herzig et al (16) conducted in Boston in 2009. They evaluated the 
association between acid suppressive therapy and hospital-acquired pneumonia. The 
authors found that hospital-acquired pneumonia was higher in the group exposed to acid 
suppressive therapy (4.9%) than in the unexposed group  (2%) with a 95% confidence 
interval of 2.3 - 2.8. They concluded that acid suppressive therapy was associated with a 
30% increase in the risk of hospital-acquired pneumonia.  
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The gastrointestinal tract has many defence mechanisms, such as gastric acidity and an 
intact gastric mucosa. Decrease in gastric acidity leads to changes in the microbial flora 
with bacterial overgrowth causing diarrhea (24). Diarrhoea is the most frequent adverse 
event in the long-term use of PPIs with a reported incidence ranging between 3.7 and 
4.1% (49).  
 
Salmonella, Campylobacter and Clostridium difficile are some of the organisms that cause 
GIT infection associated with the use of PPIs. The risk of infection is increased by 1.46 for 
Campylobacter and 1.2 for Salmonella in patients on PPIs. The use of PPIs for longer 
than a month confers a ten-fold risk of developing Campylobacter related infection (28, 49, 
50).  
 
Links have been made between PPI use and Clostridium difficile. PPIs increase the 
incidence of Clostridium difficile associated diarrhoea by two fold (30). The proposed 
mechanism for the increased risk is that gastric acid suppression allows ingested spore 
survival in the upper gastrointestinal tract and eventual proliferation in the colon (44, 50). 
The risk increases with high dose of PPIs and long duration of treatment.  
 
Acid suppression from the PPIs leads to a rise in pH in the small intestine. This impairs 
calcium absorption, which is greatly enhanced by the presence of hydrochloric acid in 
normal physiology. This may lead to increased parathyroid hormone levels resulting in 
accelerated bone resorption and an increased risk of bone fractures (30, 51). Yang et al 
(52) conducted a nested case control study using the General Practice Research 
database in the United Kingdom. Authors evaluated an association between PPIs and 
H2RA use and the development of hip fractures. The risk of hip fracture was significantly 
higher in patients on long-term high dose PPIs (>1yr), and it increased with increasing 
duration of treatment.   
 
Gastric acid is required for the release of cobalamin from dietary proteins, suppression of 
gastric acid secretion impairs this process thus impairing the absorption of vitamin B12 
(49). 
 
There is concern that patients who are on PPIs may develop rebound hypersecretion of 
gastric acid and hypergastreamia once they discontinue PPI treatment (30). 
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PPIs are metabolised in the liver via the cytochrome P450 enzyme system. The potential 
for individual PPIs to influence P450 enzyme activity raised a concern about possible 
drug-drug interaction. Certain PPIs may slow the hepatic metabolism of certain drugs that 
are metabolised by the P450 enzyme system. This becomes a concern when the drugs 
involved have a narrow therapeutic index and marginal increases in plasma concentration 
may result in serious clinical adverse events (44).  
 
Clopidogrel is a prodrug that is activated in the liver by the same isoenzyme that is 
responsible for the metabolism of PPIs. There are studies that suggest that the 
concomitant use of PPIs and clopidogrel may lead to suboptimal therapeutic levels of 
clopidogrel and therefore suboptimal clinical efficacy (44, 53). 
 
Ho et al (54) conducted a retrospective cohort study across Veterans Affair Hospitals in 
USA between October 2003-January 2006 on patients taking clopidogrel after discharge 
post-acute coronary syndrome (ACS). The reported risk of hospitalisation for recurrent 
ACS was higher (14.6%) in the group taking PPIs plus clopidogrel compared to the group 
who were taking clopidogrel alone (6.9%). 
 
The COGENT trial (55) was an international study conducted between January 2008-
December 2008 that looked at giving clopidogrel with or without omeprazole in coronary 
artery disease. The primary cardiovascular end point was a composite of death from 
cardiovascular causes, nonfatal myocardial infarction and revascularisation. The two 
groups did not differ significantly in the rate of serious adverse events. The trial was 
terminated prematurely due to lack of funds.   
 
It is of paramount importance for the clinician to appropriately assess the risk of patient to 
develop stress ulcer in order to avoid the unwanted side effects that compromise quality of 
life for the patient (2, 24). 
 
2.6.6 Overuse of proton pump inhibitors 
In a retrospective study by Farrel et al (4) conducted in Pennsylvania between December 
2006-March 2007, they studied all ICU admissions for four months looking at risk factors 
for stress ulcer bleeding. Results showed that of all the ICU admissions, 87% received 
stress ulcer prophylaxis and 68% of patients without any risk factors were placed on 
prophylaxis on ICU admission.  
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In another study that was done by Nardino et al (14) in Yale Connecticut they looked at 
patients admitted to a general medicine unit over a period of three months. They 
evaluated the indications for SUP. In the group that received SUP, 65% had no 
indications and concluded that there was overuse of SUP. 
 
In the Netherlands, Van Vliet et al (15) conducted a study  from October 2004-April 2005 
with the aim of determining the indications for PPIs use in two pulmonary medicine wards 
and to assess whether the use was appropriate. The study found that in 40% of the 
patients using PPIs on admission, there was no indication for their use, which 
demonstrated overuse. 
 
Heidelbaugh et al (17) conducted a study in a multi-specialty teaching hospital in 
Michigan. They looked at all outpatients who had received a prescription for a PPI 
between February 2006 and January 2007. The authors found that 36% had no indication 
for PPI therapy. The total cost of inappropriate PPI use was $ 233,994 based on over the 
counter PPI cost and $ 1,566,252 based on average wholesale price costs in that time 
period. They concluded that PPIs were overused with a consequence of a substantial 
burden of cost to health care. 
 
In an observational study conducted by Slattery et al (45) in Dublin, Ireland over a three 
month period, the authors found that intravenous PPI use in hospital was inappropriate. 
The cost of standard IV PPI doses is approximately  £5 (2007) excluding pharmacy, 
nursing and infusion costs, compared to oral formulation that ranges from 50p to £1 
(2007). This highlights the health cost implications of inappropriately used intravenous 
PPIs. 
 
2.7 ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis 
The University of Arizona under contract of ASHP prepared the ASHP Therapeutic 
Guidelines on Stress Ulcer Prophylaxis. The authors did a detailed literature search on 
Medline from the period 1966 -1997 and International Pharmaceutical Abstracts (IPA) 
from 1970-1997. The guidelines that were formulated were categorised according to the 
strength of the evidence (8). 
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Aim of the guidelines 
These guidelines are for stress ulcer prophylaxis in the acute setting immediately after the 
onset of the “stressor”, where the stress response is still active. They are not applicable in 
chronic disease states. 
 
Summary of the recommendations 
Indication for prophylaxis: 
Adults: prophylaxis is recommended in patients with coagulopathy or patients on 
mechanical ventilation for more than 48h. Also recommended in patients with more than 
one of the following sepsis, burns, renal failure, hepatic failure, high dose steroids, 
anticoagulation therapy, major surgery, spinal cord injury. 
 
Agent of choice 
Adults and paediatrics: this should be according to the institution. 
 
Adverse effects 
Adults and paediatrics: drugs used for SUP to be avoided in patients with a positive 
history of severe adverse effects. 
 
 
Monitoring 
Adults and paediatrics: patients on SUP to be monitored for gastrointestinal bleeding and 
adverse effects. 
 
Prevention of rebleeding 
Adults and paediatrics: currently no concrete evidence however increasing the dosage of 
the prophylactic agent should be considered. 
 
Non-ICU patients 
Adults and paediatrics: SUP not recommended in non-ICU patients 
 
Institution-specific guidelines 
Adults and paediatric: it is recommended that institutions develop guidelines that are more 
suited to their resources. 
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Criticism of the guidelines: they were published in 1999 and certain aspects are outdated. 
The recommendation of agent of choice being according to institution is outdated. Current 
literature has demonstrated PPIs as being the superior agent and currently recommended 
as agent of choice for SUP (Table 2.1). The length of stay in ICU is currently infrequently 
used in the literature as a minor risk factor and anticoagulants are recognised as a minor 
risk factor (1, 9). 
 
2.8 Summary 
This chapter discussed the physiology of gastric acid secretion, pathophysiology, risk 
factor, prophylaxis of stress ulcers. The pharmacology of PPIs was also discussed as well 
as problems surrounding the appropriate and inappropriate use of PPIs. The next chapter 
will discuss the research methodology of this study. 
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CHAPTER THREE 
RESEARCH METHODOLOGY 
3.1 Introduction 
In this chapter the problem statement, aim and objectives, ethical considerations, 
research methodology and the validity and reliability of this study are discussed.  
 
3.2 Problem statement 
It is well documented that patients in ICU are at an increased risk of developing stress 
ulcers (4).  PPIs are regarded as the drug of choice for prophylaxis (10), and overuse of 
these drugs has serious medical implications such as drug-drug interactions (42), adverse 
effects like hospital acquired pneumonia (16) and has financial implications (17).  
 
There are guidelines in terms of risk stratification as to which patient should be put on 
prophylaxis for stress ulcers (8). Despite good intentions, there is often a gap between 
evidenced based guidelines and actual clinical practice (18). The use of PPIs is one area 
where such a gap exists. It has been shown internationally that prophylaxis for stress 
ulcers is still overused in ICU (4). Nardino et al (14) showed that up to 65% of patients 
receive stress ulcer prophylaxis without any risk factors in the general medical unit. It is 
not known whether PPIs are overused in the ICUs of South African hospitals, specifically 
Chris Hani Baragwanath Academic Hospital (CHBAH), Charlotte Maxeke Johannesburg 
Academic Hospital (CMJAH) and Helen Joseph Hospital (HJH). 
  
3.3 Aim and objectives of the study 
3.3.1 Aim 
The aim of this study was to describe the use of PPIs in ICU patients at CHBAH, CMJAH 
and HJH over a three-month period. 
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3.3.2 Objectives 
The objectives of this study were to: 
• describe the use of SUP in the ICUs 
• describe the risk factors that necessitate the initiation of SUP 
• describe the SUP received by patients with no risk factors 
• describe the risk factors in those patients inappropriately not on SUP 
• describe the appropriate use of PPIs in ICU versus the inappropriate use according to 
the risk factors of the patient as per ASHP guidelines. 
 
3.4. Ethical considerations 
Ethical approval was obtained from the Human Research Ethics Committee (Medical) and 
the Post-Graduate Committee of the University of the Witwatersrand (Wits) (Appendix 
1&2). 
 
Once these requirements were fulfilled, consent to perform the study was attained from 
the Chief Executive Officer of CHBAH, CMJAH, HJH (Appendix 3,4&5) and consent was 
obtained from the respective ICU directors (Appendix 6&7). 
 
The data collection sheet (Appendix 8) did not reflect patients’ name or hospital numbers. 
The researcher kept a separate list of patients’ names in order to link them to participant 
number should it be necessary. Only the researcher was privy to the names of the 
patients, this ensured confidentiality, privacy and anonymity of patients’ information. Data 
will be stored securely for a period of six years following completion of the study. 
 
Due to the retrospective nature of the study the researcher was not able to intervene 
where there was inappropriate treatment according to the ASHP guidelines. The 
researcher abided by the principles of the Declaration of Helsinki (21) and the South 
African Good Clinical Practice Guidelines (22). 
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3.5. Research methodology 
3.5.1 Research design 
A retrospective, descriptive, contextual study design was used. 
 
A retrospective study uses existing data that has been recorded for purposes other than 
research (56). This study was retrospective in nature as it involved the analysis of 
recorded data from patients’ ICU charts.  
 
A descriptive study aims to describe a situation or identify problems through observation, 
description or classification, without manipulating variables (57). This study is descriptive 
in nature as it described the use of PPIs in ICU as appropriate or inappropriate according 
to ASHP guidelines on stress ulcer prophylaxis.  
 
A contextual study is one that takes place in a specific location (58). This study is 
contextual, as it was conducted in the ICU’s of specific hospitals.  
 
3.5.2 Study population 
The ICU charts of all adult patients admitted to CHBAH, CMJAH and HJH ICUs during the 
study period formed the population group studied. 
 
3.5.3 Study sample 
Sample size 
The number of patients admitted into the ICUs over a three-month period determined the 
sample size. 
 
Sampling method 
Convenience, consecutive sampling of ICU charts was used. Convenience sampling 
involves the choice of readily available subjects or objects for the study (58). Consecutive 
sampling entails utilising every available individual or event within an accessible 
population (59). 
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3.5.4 Inclusion and exclusion criteria  
Inclusion criteria 
All complete and legible ICU charts of adult patients admitted to ICU in CHBAH, CMJAH 
and HJH during the study period. 
 
Exclusion criteria 
The ICU charts of patients with the following were excluded: 
• existing upper gastrointestinal bleeding 
• previous total gastrectomy 
• died or discharged 24 hours after admission 
• on PPIs prior to admission. 
 
3.5.5 Data collection 
A data collection sheet (Appendix 8) was used to collect data from ICU charts of patients 
admitted into ICU during the study period. 
The data collection sheet was used to capture the following data:  
• Age 
• Gender 
• Admission diagnosis 
• Major risk factors: 
• Mechanical ventilation longer than 48h 
• Coagulopathy 
• Minor risk factors:  
• Sepsis 
• Burns 
• Renal failure 
• Hepatic failure 
• High dose glucocorticoids 
• Heparin 
• Warfarin 
• Major surgery 
• Spinal cord injury. 
 
 
 28 
 
Stress ulcer prophylaxis received in ICU: 
• Drug name 
• Dose  
• Route of administration 
• Duration of prophylaxis 
• Method of administration (infusion or bolus) 
• Introduction of feeds (after how many days of starvation). 
The researcher collected the data personally and the data were entered into a Microsoft 
Excel® spreadsheet. Data were collected from ICU charts dated from 1st August up to and 
including 31st October 2013.  
  
3.5.6 Data analysis 
Patients were categorised into the following groups: 
• one or more major risk factors present 
• two or more minor risk factors present 
• no major or minor risk factors present 
• patients not on PPIs but meet the criteria for SUP 
• patients who received PPIs for SUP 
• patients who received other drugs for SUP 
• appropriate versus inappropriate use of PPIs 
• overuse of SUP. 
 
Patient demographics were described using descriptive statistics: mean and standard 
deviation where the distribution was normal, median and interquartile range, where the 
distribution was not normal. 
 
3.6 Validity and reliability of the study 
Validity is the extent to which the instrument actually reflects or measures what it is 
supposed to measure (57). Reliability is concerned with how consistently the 
measurement technique measures a variable or concept (57). 
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Validity and reliability were maintained by the following: 
• the data were collected from patients’ records by a single researcher 
• standardised data collection sheet was used  
• the risk factors that were used in the study were clearly defined 
• appropriate study design was used 
• data analysis was done in consultation with a biostatistician.  
 
3.7 Summary 
In this chapter the problem statement, aim and objectives, ethical considerations, 
research methodology and the validity and reliability of this study were discussed. 
Discussion of the research methodology included the research design, study population, 
study sample, data collection and data analysis. In the next chapter, results of the study 
as per objectives are presented and discussed. 
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CHAPTER FOUR  
RESULTS AND DISCUSSION 
4.1 Introduction 
This chapter presents the results of the study and the discussion thereof according to the 
objectives. 
The objectives of this study were to: 
• describe the use of SUP in the ICUs 
• describe the risk factors that necessitate the initiation of SUP  
• describe the SUP received by patients with no risk factors 
• describe the risk factors in those patients inappropriately not on SUP 
• describe the appropriate use of PPIs in ICU versus the inappropriate use according to 
the risk factors of the patient as per ASHP guidelines. 
 
4.2 Sample realisation 
A total of 174 patients were included in the study. Of the 174 patients in this study, 156 
were on SUP and 18 patients who should have been on SUP according to the guidelines 
were not. 
 
4.3 Results 
The numbers in percentages were rounded off to one decimal place so they may not add 
up to 100%. The data was collected from ICU charts dated from 1 August up to and 
including 31 October 2013 across three ICUs. 
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4.3.1 Demographic data 
Of the 174 patients, 49% (85) were male and 51% (89) were female. The minimum age 
was 18 years and maximum 88 years and the average age was 44 years (SD17.6). The 
patients came from nine disciplines as shown in Table 4.1.  
 
Table 4.1 Disciplines patients were referred from 
Discipline Number Percentage 
General surgery 46 26.4 
Trauma 29 16.7 
O&G 15 8.6 
Orthopaedic 7 4.0 
Vascular surgery 6 3.4 
Internal medicine 60 34.5 
Urology 2 1.1 
Neuro surgery 3 1.7 
ENT 6 3.4 
Total 174 99.8 
 
The minimum duration on SUP was one day and maximum was 23 days. The minimum 
starvation period was one day and the maximum was five days. The starvation period of 
the patients on SUP is presented in Table 4.2. 
 
Table 4.2 Starvation periods of the patients on SUP 
Period of starvation Number  Percentage 
0 day 36  23.1 
1 day 78  50 
2 days 21  13.5 
3 days 16  10.3 
4 days  3  1.9 
5 days 2  1.3 
Total 156  100 
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4.3.2 Objective: describe the use of SUP in the ICU 
Of the 174 patients included in the study 156 were on SUP and 18 who should have 
received SUP according to the ASHP guidelines and were not on SUP. Table 4.3 shows 
SUP practice in the ICUs. 
 
Table 4.3 SUP practice in the ICUs 
Type of SUP Number  Percentage  
PPIs 49  31.4 
H2RA 80  51.3 
Sucralfate 27  17.3 
Total 156  100 
 
Of the 156 patients that were on SUP, 59.6% (93) received SUP intravenously and 40.4% 
(63) orally. This data is represented in Table 4.4  
 
Table 4.4 Route of administration of SUP 
Route  Number  Percentage  
Oral  63 40.4 
Intravenous  93 59.6 
Total  156  100 
 
Of the 93 patients that received their SUP intravenously, 81,8% (76) received intravenous 
bolus doses and 18.2% (17) received an infusion. 
 
4.3.3 Objective: describe the risk factors that necessitate the initiation of 
SUP 
Of the 156 patients on SUP, 60.9% (95) were appropriately prescribed SUP and 39.1% 
(61) were receiving SUP inappropriately according to the ASHP guidelines. Of these 95 
patients, 41 had either 1 or both major risk factors only (i.e. no minor risk factors) that 
initiated the prescribing of SUPs. This is shown in Table 4.5 
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Table 4.5 Major risk factors only as an indication for SUP 
Major risk factor Number Percentage  
Mechanical ventilation 39  95.1 
Coagulopathy 1  2.4 
Both  1  2.4 
Total  41  100 
 
 
Forty three (45.3%) of the 95 patients appropriately prescribed SUP according to the 
ASHP guidelines had 1 major risk factor and ≥ 1 minor risk factors. This is shown in Table 
4.6 
 
Table 4.6 Major and minor risk factors as an indication for SUP 
Major and minor risk factors Number Percentage 
 Mechanical ventilation and 1 minor risk factor  31 72.1 
Mechanical ventilation and 2 minor risk factors  6  14.0 
Mechanical ventilation and 3 minor risk factors  5  11.6 
Coagulopathy and 1 minor risk factor 1  2.3 
Total 43  100 
 
Ten (10.5%) of the 95 patients appropriately prescribed SUP according to the ASHP 
guidelines had both major risk factors and ≥	 1	 minor	 risk factors. This is shown in Table 
4.7 
Table 4.7 Both major and minor risk factors as an indication 
for SUP 
Major and minor risk factors Number Percentage  
Both major and 1 minor risk factor 6  60 
Both major and 2 minor risk factors 2 20 
Both major and 3 minor risk factors 2   20 
Total  10  100 
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One (1.1%) patient of the 95 on SUP had 3 minor risk factors that necessitated initiation of 
SUP and no major risk factors. 
 
The SUP received by the 95 patients that were appropriately on SUP is presented in 
Table 4.8. 
 
Table 4.8 SUP received by patients with risk factors 
Type of SUP Number Percentage  
PPIs  32 33.7 
H2RA 42  44.2 
Sucralfate 21 22.1 
Total 95  100 
 
 
4.3.4 Objective: describe the SUP received by patients with no risk factors 
Of the 156 patients on SUP, 39.1% (61) had no risk factors that required the initiation of 
SUP. The SUP received by these patients is shown in Table 4.9 
. 
 
Table 4.9 SUP received by patients with no risk factors 
Type of SUP Number  Percentage  
PPIs 17  27.9 
H2RA 38  62,3 
Sucralfate 6  9.8 
Total 61  100 
 
4.3.5 Objective: describe the risk factors in those patients inappropriately 
not on SUP 
Eighteen patients with risk factors that qualified them for SUP according to the ASHP 
guidelines were not receiving any prophylaxis. The risk factors of these 18 patients are 
shown in Table 4.10 
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Table 4.10 Risk factors of patients inappropriately not receiving SUP  
Risk factor(s) Number 
(%) 
Percentage  
Both major plus minor risk factors 2  11.1 
0ne major plus minor risk factors 7  38.9 
Major risk factors only 7  38.9 
Minor risk factors only 2  11.1 
Total 18  100 
 
 
4.3.6 Objective: describe the appropriate use of PPIs in ICU versus the 
inappropriate use according to the risk factors of the patient 
Of the 156 patients on SUP, 60.9% (95) with a 95% CI of 53.1-68.2% were appropriately 
on SUP and 39.1% (61), 95%CI of 31.8-46.9% were inappropriately on SUP. Of the 95 
patients that were appropriately on SUP, 33.7% (32) were appropriately on PPIs and 
66.3% (63) who should have been on PPIs were on other SUP agents. Of those patients 
who were inappropriately on SUP, 27,9% was on PPIs and 72.1% were on other agents 
as first line for SUP. 
 
There were 18 patients who according to the ASHP guidelines had risk factors that 
qualified them for SUP but were inappropriately not on SUP. This SUP should have been 
PPIs. 
 
Of the 174 patients included in the study, 64.9% (113) qualified for SUP according to the 
ASHP guidelines (i.e. the 95 who were appropriately on SUP and the 18 who should have 
been on SUP) and should have been on PPIs. Only 28.3%(32), 95% CI of 20.8-37.3% 
were on PPIs, leaving 71.7% (81), 95%CI of 64.3-78.1% inappropriately not on PPIs. This 
is illustrated in Figure 4.1  
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Key 
 
 
   
 
 
 
 
Figure 4.1 The appropriate versus the inappropriate use of proton pump 
inhibitor 
 
 
Figure 4.1 shows an underuse of PPIs of 71.7% (81of 113), 95% CI of 64.3-78.1% and 
only 28.3% (32), 95% CI of 20.8-37.3% appropriate use.  
 
 Appropriately on PPIs 
 Inappropriately on SUP 
 Inappropriately not on PPIs 
SUPPPIs 
Patients in study  
174 
Patients on SUP 
156 (89.7%) 
Appropriately on SUP 
95(60.9%) 
PPIs 
32(33.7%) 
H2RA 
42(44.2%) 
Sucralfate 
21(22.1%) 
Inappropriately on SUP 61(39.1%)	  
PPIs 
17(27.9%) 
H2RA 
38(62.3%) 
Sucralfate 
6(9.8%) 
Patients inappropriately not on SUP  
18 (10.3%) 
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4.4 Discussion 
Stress ulcers in critically ill patients increase morbidity and mortality (9). The adoption of 
SUP as part of patient care in the ICU has led to the significant decline in the incidence of 
CSB over the years from 5.3 to 33% in the 1970’s to < 5% in the 2010’s (1) . The literature 
shows that PPIs have a superior efficacy in preventing CSB compared to the other agents 
(7, 32). Levy et al (35) compared omeprazole and ranitidine and the results of his study 
showed significantly more CSB in the ranitidine group. A meta-analysis by Alhazzani et al 
(7) also concluded that there is less CSB when PPIs are used as compared to H2RAs. 
This body of evidence led to the use of PPIs as first line agents for SUP, which later on 
brought about the concern of inappropriate overuse of PPIs (33). 
 
In our study a total of 39.1% of patients on SUP had no indication for SUP according to 
the ASHP guidelines reflecting overuse of SUP. The significance of this lies in the cost 
incurred (2, 13) and the unnecessary exposure of critically ill patients to side effects of the 
drugs used for SUP (16, 50). This is in keeping with a study conducted by Van Vliet et al 
(15) where they found an overuse of SUP of 40%. Other studies had significantly higher 
incidence of overuse, Farrell et al (4) had 68% overuse, Zeitoun et al (60) found 67% 
overuse and Mohebbi et al (33) found 66% overuse. 
 
Analysis of prescription practice in the patients that were on SUP yielded the following: 
H2RA were the most commonly used at 51.3%, followed by PPIs at 31,4% and sucralfate 
at 17.3%. Nardino et al (14) had 62% H2RA, 33% PPI and 5% sucralfate. Zeitoun et al 
(60) found 61.6% PPIs, 38.4% H2RA and non on sucralfate. Compared to other studies 
we had a higher use of sucralfate. There are several factors that influence the choice of 
drug used for SUP, such as cost, efficacy, side effect profile, availability and hospital 
practice. A meta-analysis done by Barkun et al (32) showed that PPIs are the superior 
agent for SUP. In our study only the use of PPIs as SUP was deemed as appropriate 
practice, and the use of any other drug was deemed as inappropriate (11, 12, 23, 35).  
 
 Of the 113 patients that qualified for SUP only 28.3% were on PPIs showing underuse of 
71.7% (81). PPIs when used appropriately in patients at high risk of developing SRMD are 
cost effective compared to H2RA as shown by Barkun (23). In their study where they were 
assessing the cost-effectiveness of SUP using either PPIs or H2RA, they found PPIs to be 
more cost effective taking into consideration the risk of VAP and number of days in ICU. 
Schupp et al (61) came to the same conclusion in their study. However Mac Laren and 
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Campbell (62) have different conclusion to the ones above, their cost effectiveness 
analysis suggest that H2RA reduce cost with comparable clinical outcomes to PPIs and 
recommend prospective study to validate their finding. 
 
Most patients received medication intravenously (59.6%) compared to the oral route 
(40.4%). Alsultan et al (63) showed 19% inappropriate intravenous PPI use in ICU and 
90.4% inappropriate intravenous PPI use in non-ICU patients. Zeitoun et al (60) found 
71.6% of the patients on intravenous treatment could have tolerated oral medication. 
Literature shows that intravenous administration of PPIs has the same clinical outcome as 
the oral route (45, 46). The oral route must be utilised whenever possible as it has the 
added advantage of decreasing cost (45) and achieving the same clinical outcome. 
 
The maximal number of days that a patient was on SUP was 23. The risk of developing 
SUP associated GIT infection and hospital acquired pneumonia is proportional to the 
duration of SUP (16, 64). SUP must therefore be discontinued upon resolution of risk 
factors (24, 30). Fohl and Regal (48) site the dose as well as duration of treatment as risk 
factors for developing pneumonia specifically when PPIs were used as SUP. In our study 
the duration of treatment was assessed while the patients were in ICU and not assessed 
upon discharge. In the literature generally authors commented on the number of patients 
discharged to the general ward on SUP inappropriately but not the number of days on 
SUP while in ICU. The common trend was that a high number of patients were discharged 
to the ward inappropriately on SUP ((4, 60, 63). 
In our study the most common practice was early feeding. The longest starvation period 
was five days. Feeding has the advantage of maintaining gut integrity and confers 
mucosal protection (1, 24, 30). At the same time feeding mechanically ventilated patients 
is associated with the risk of VAP (65, 66). These are some of the factors that have to be 
considered when choosing a SUP agent. Giving protection against SRMD without 
increasing the risk of VAP in these patients is one of the corner stones of SUP 
management (67). Although the risk of VAP when using PPIs is equal to that of H2RA, 
PPIs give more protection against CSB and are the agent of choice (7, 33).  
 
In 39.1% SUP was used inappropriately and only a small number (27.9%) of those 
patients were on PPIs. Other agents were inappropriately used as first line agents for 
SUP. Of the 95 patients on SUP only 33.7% were on PPIs and 66.3% were on other 
agents.  
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There was a small group of patients (10.3%) who had risk factors that qualified them for 
SUP but did not receive any SUP. This group of patients had a high risk of developing 
CSB, which can be reduced by 50% with the use of SUP (9). Van Vliet (15) in his study 
had 6% of patients not on SUP even though they should have been. This was far less 
compared to our results. Most studies did not comment on underuse of SUP. 
 
4.5 Summary 
In this chapter the results of the study as defined by the objectives were presented 
followed by a discussion of the results. In the following chapter, the summary, limitations, 
recommendations and conclusion of this study will be presented.
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CHAPTER FIVE 
SUMMARY, LIMITATIONS, RECOMMENDATIONS AND 
CONCLUSION 
 
5.1 Introduction 
In this chapter the summary of the study, main findings and research methodology of this 
study will be presented. The limitations will be explored, recommendations will be made 
and a conclusion presented. 
 
5.2 Summary of the study 
 5.2.1 Aim 
The aim of this study was to describe the use of PPIs in ICU patients at CHBAH, CMJAH 
and HJH over a three-month period. 
 
5.2.2 Objectives 
The objectives of this study were to: 
• describe the use of SUP in the ICUs 
• describe the risk factors that necessitate the initiation of SUP 
• describe the SUP received by patients with no risk factors 
• describe the risk factors in those patients inappropriately not on SUP 
• describe the appropriate use of PPIs in ICU versus the inappropriate use according to 
the risk factors of the patient as per ASHP guidelines. 
 
5.2.3 Methodology 
A retrospective, descriptive, contextual study design was used. The ICU charts of adult 
patients admitted to CHBAH, CMJAH and HJH ICUs that fulfilled the inclusion and 
exclusion criteria from August to October 2013 were included in the study.  
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A data collection sheet (Appendix 8) was used to collect data from ICU charts of patients 
admitted into ICU during the study period. Data were entered into a Microsoft excel 
spreadsheet and analysed in consultation with a biostatistician using STATA 12.5. 
 
5.2.4 Main findings   
A total of 174 patients were included in the study. Of these patients 156 were on SUP, 
60.9% of them were appropriately started on SUP and 39.1% were inappropriately on 
SUP indicating overuse. Of the 156 patients on SUP, 51.3% were on H2RA, 31.4% were 
on PPIs and 17.3% were on sucralfate. The number of patients that actually qualified for 
SUP was 113. In that group of patients only 28.7% were on PPIs and the remainder of the 
patients 71.7% were either on other agents as first line or were not on any SUP, reflecting 
an underuse of PPIs. 
 
5.3 Limitations 
This was a retrospective study looking at patient’s charts, which meant that the data 
obtained depended on the accuracy of the medical record keeping. 
  
The route of administration of SUP was delineated to oral or intravenous but the 
intravenous route was not further analysed to determine if it was appropriate or the patient 
could have tolerated oral SUP. It was not part of the scope of our study. This is important 
as it has impact on cost.  
 
The univariate/multivariate analysis would have been useful to determine which risk 
factors prompted clinicians to start SUP, but the study was not powered for this.   
 
The practice of discontinuation of SUP was not assessed in this study, follow up on 
continued SUP use in the general ward was beyond the scope of this study.  
This study was contextually done in the CHDAH, CMJAH and HJH therefore the results 
may not be generilisable to other ICUs.  
 
 
 
 
 
 42 
5.4 Recommendations 
5.4.1 Clinical practice 
• Conducting a survey in the form of a questionnaire to determine the level of 
knowledge and then addressing the deficiency of knowledge where applicable 
• Having a set of printed guidelines distributed among new members of the ICU might 
add to their knowledge. 
 
 5.4.2 Further research 
• A study looking into how medical personnel choose the drugs used as SUP, what 
informs their decision and the role played by cost and availability of PPIs as 
contributing factor to the underuse 
• A study analysing the various practices in these ICUs can add value by identifying 
substandard practice and improving practice where it is applicable. 
 
5.5 Conclusion 
Our study found inappropriate overuse of SUP according to the ASHP guidelines, 
however there were patients who qualified for SUP but were not on SUP. In the group of 
patients that were appropriately on SUP, a large number of them were on other agents 
and not PPIs even though it is the drug of choice.
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APPENDIX 8  
Demographics    
Age     
Gender    
Admission diagnosis   
Risk factors   
Major    
Mechanical ventilation 
more than 48 hours 
  
Coagulopathy    
Minor    
Sepsis    
Burns    
Renal failure   
Hepatic failure   
Use of high dose steroid 
more than 250 mg/day 
  
Heparin    
Warfarin    
Major surgery   
Spinal chord injury   
Stress ulcer 
prophylaxis  
  
Drug    
Dose    
Route of administration   
Mode of administration 
(infusion/bolus) 
 
 
 
Introduction of feeds  
(days of starvation) 
  
 
